The latest ENGOT meeting, held on April 3-4, 2025, gathered representatives from all ENGOT groups to review progress across numerous ongoing and completed trials, present updates from working groups, and discuss strategic priorities.

CEEGOG was represented by its Chair Prof. David Cibula and Administrative Manager Mrs. Ivana Nohová. From the CEEGOG studies, updates on the SENTIX and CERVANTES were presented.

Highlights included:

• Clinical Trials – Updates on recruitment, regulatory progress, and key milestones across multiple ENGOT model A, B, and C studies in ovarian, endometrial, and cervical cancer s well as an overview of new proposals, including all GCA 2024 trial proposals.
• Scientific Achievements – Several trials are nearing completion, with data expected to be presented at major conferences such as ESGO, ESMO, and ASCO in 2025–2026.
• Working Group Reports – Operational updates, improved templates for contracts and trial budgeting, and new guidelines for ENGOT presentations to pharmaceutical companies.
• Strategic Discussions – Strengthening academic trial support, refining publication rules, ensuring representation in trial steering committees, and planning for future leadership rotations.
• Collaborative Initiatives – Expansion of the Rare Tumour Registry, TR group biobank projects, and ESGO database.

CEEGOG is now a full partner in most clinical trials which influence the standard of care. We thank all participating sites for their interest in offering new treatment options to their patients and for their commitment to clinical research as a whole.